Memory Clinic and Psychiatric Department, Donauspital Sozialmedizinisches Zentrum Ost, Langobardenstrasse 122, 1220, Wien, Austria.
J Neural Transm (Vienna). 2011 Aug;118(8):1255-9. doi: 10.1007/s00702-011-0623-8. Epub 2011 Apr 2.
Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this 'real-life' setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.
盐酸美金刚是一种 N-甲基-D-天冬氨酸（NMDA）受体拮抗剂，已获准用于治疗中重度阿尔茨海默病（AD）。我们在奥地利开展了一项为期 4 个月的、上市后的、观察性研究，共纳入 377 例中重度 AD 门诊患者，评估盐酸美金刚的疗效。在这种‘真实世界’的环境下，盐酸美金刚耐受性良好，可改善认知功能（简易精神状态检查量表）、日常生活活动能力（日常生活活动评分）和总体功能（临床总体印象量表）。在预先治疗和未经治疗的亚组患者中，治疗效果均明显。
